Association of molecular subtype, proliferation, and immune genes with efficacy of carboplatin versus gemcitabine addition to taxane-based, anthracycline-free neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC): Results of the randomized WSG ADAPT-TN trial.

作者
Oleg Gluz,Cornelia Liedtke,Aleix Prat,Matthias Christgen,Daniel Gebauer,Ronald Ernest Kates,Eva‐Maria Grischke,Helmut Forstbauer,Michael Braun,Mathias R. Warm,John Hackmann,Christoph Uleer,Bahriye Aktas,Claudia Schumacher,Sherko Kümmel,Rachel Wuerstlein,Enrico Pelz,Ulrike Anneliese Nitz,Hans Heinrich Kreipe,Nadia Harbeck
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:35 (15_suppl): 573-573 被引量:3
标识
DOI:10.1200/jco.2017.35.15_suppl.573
摘要

573 Background: In the ADAPT-TN neoadjuvant trial, 12-week nab-paclitaxel (nab- pac)+carboplatin (carbo) was highly effective and superior to nab-pac+gemcitabine (gem). However, within TNBC, reliable predictive markers for carbo use have yet to be identified. Methods: Patients with early TNBC (centrally confirmed) were treated by nab-pac 125 mg/m2 with either carbo AUC2 or gem 1000 mg/m2 d 1,8 q21 given for 4 cycles. Genomic data (80 genes) and Prosigna (PAM-50) scores were available in 306 pre-therapeutic samples of 331 treated patients. Fisher’s exact test was performed for pCR differences; associations of continuous measurements or scores with pCR were analyzed by the Mann-Whitney statistic. Results: pCR was 44.5% to 28.4% (p=.004) in favor of nab-pac - carbo. Specifically within the carbo- containing arm, immunological (CD8, PD1, PFDL1) genes and proliferation markers (proliferation score and ROR scores, MKI67, CDC20, NUF2, KIF2C, CENPF, EMP3, TYMS) were positively associated with pCR (p<.05 for all). Specifically within the gem-arm, angiogenesis genes were negatively associated with pCR (ANGPTL4: p=.05; FGFR4: p=.02; VEGFA: p=.03). In the whole collective, basal-like (83.3%) was favorable for pCR (38% vs. 20%, p=.015) compared to other subtypes (HER: 6.4%; luminal-A: 1.7%; normal: 8.7%), as was lower HER-2 score (p<.001). Proliferation was positively associated with pCR: i.e., Pam50 proliferation score, ROR scores (all p<.004), and higher Ki67 by central IHC (p<.001) -- though not MKI67 RNA expression, despite their moderate correlation. Conclusions: In early TNBC, basal-like subtype, higher Ki67 (by IHC), and lower HER-2 score were associated with chemo-sensitivity for both neoadjuvant arms. Chemo-resistance pathways differed between the two taxane-based combinations (low proliferation and immune marker gene expression for carbo, high angiogenesis for gem). The positive predictive impact of immunological genes in the nab-pac - carbo arm could influence optimal patient selection for immune-modulative therapy. Clinical trial information: NCT01815242.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
德烁完成签到,获得积分10
1秒前
敌敌薇完成签到,获得积分10
1秒前
英姑的应助被刻苦月亮采纳,获得10
3秒前
4秒前
整齐白秋完成签到 ,获得积分10
4秒前
Owen的应助被78j3采纳,获得10
4秒前
Ava的应助被姜昊彤采纳,获得10
4秒前
爆米花的应助被xxxx采纳,获得10
5秒前
肖坤完成签到 ,获得积分10
5秒前
5秒前
情怀的应助被科研通管家采纳,获得10
5秒前
xzy666的应助被科研通管家采纳,获得10
5秒前
斯文败类的应助被科研通管家采纳,获得10
5秒前
CAOHOU的应助被科研通管家采纳,获得10
5秒前
秋风的应助被科研通管家采纳,获得10
6秒前
说说发布了新的文献求助10
6秒前
斯文败类的应助被科研通管家采纳,获得10
6秒前
科研通AI65的应助被科研通管家采纳,获得10
6秒前
Youdge的应助被科研通管家采纳,获得10
6秒前
深情安青的应助被科研通管家采纳,获得10
6秒前
月白完成签到,获得积分10
6秒前
情怀的应助被科研通管家采纳,获得10
6秒前
ding的应助被科研通管家采纳,获得10
6秒前
归宁发布了新的文献求助10
7秒前
丘比特的应助被科研通管家采纳,获得10
7秒前
李爱国的应助被科研通管家采纳,获得10
7秒前
水弘的应助被科研通管家采纳,获得30
7秒前
7秒前
wanci的应助被科研通管家采纳,获得10
7秒前
CAOHOU的应助被科研通管家采纳,获得10
7秒前
7秒前
秋风的应助被科研通管家采纳,获得20
7秒前
7秒前
秋风的应助被科研通管家采纳,获得20
7秒前
7秒前
大模型的应助被yt采纳,获得10
7秒前
李健的应助被科研通管家采纳,获得10
8秒前
无花果的应助被wy采纳,获得10
8秒前
酷波er的应助被科研通管家采纳,获得10
8秒前
丁驰发布了新的文献求助10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8192871
求助须知:如何正确求助?哪些是违规求助? 9579281
关于积分的说明 21864358
捐赠科研通 7792445
什么是DOI,文献DOI怎么找? 3437059
关于科研通互助平台的介绍 2560639
邀请新用户注册赠送积分活动 2483928